This article is more than 5 years old. Information may no longer be current.
Biologics more often led to remission in PsA vs conventional drugs
Click Here to Manage Email Alerts
Among patients with psoriatic arthritis, biologics more often led to remission or minimal disease activity compared with conventional drugs, according to a published analysis.
“The aim of our study was to evaluate the remission or [minimal disease activity] in a group of patients with [psoriatic arthritis] consecutively in an outpatient clinic and regardless of the treatment strategy by using the composite indices validated and tailored for [psoriatic arthritis],” researchers wrote.
Investigators assessed 109 patients with psoriatic arthritis (PsA), 79 who were treated with biologics and 30 with conventional drugs. In total, 25.6% of patients were in clinical disease activity index for PsA (cDAPSA) remission, 21.1% were in DAPSA remission, 17.4% had minimal disease activity (MDA) 7/7 and 11.9% had a PsA disease score (PASDAS) of 1.9 or less. In addition, 49.5% had MDA 5/7, 73.3% had DAPSA low disease activity (LDA), 72.3% had cDAPSA LDA and 34.8% had PASDAS LDA. Furthermore, patients on biologics had a significantly reduced median DAPSA, cDAPSA, and PASDAS compared with those treated with conventional drugs, the researchers wrote. – by Will A. Offit
Disclosures: The researchers report no relevant financial disclosures.
Click Here to Manage Email Alerts